LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Aandelen Lijst・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Gesloten

SectorGezondheidszorg

66.12 0.18

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

65.34

Max

67.23

Belangrijke statistieken
By Trading Economics
Inkomsten	-317M -142M
Verkoop	98M 452M
K/W Sectorgemiddelde	25.027 49.8
Winstmarge	-31.342
Werknemers	423
EBITDA	-3.5M 281M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+40% upside

Dividenden
By Dow Jones
Volgende Winsten	11 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-1.7B 7.6B
Vorige openingsprijs	65.94
Vorige sluitingsprijs	66.12

Nieuwssentiment

By Acuity

91%

7 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

60.49 / 70.14 Steun & Weerstand

Halozyme Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 mei 2026, 23:41 UTC

Winsten

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mei 2026, 21:40 UTC

Winsten

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mei 2026, 23:34 UTC

Marktinformatie

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mei 2026, 23:13 UTC

Winsten

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mei 2026, 23:13 UTC

Winsten

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mei 2026, 23:12 UTC

Winsten

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mei 2026, 23:11 UTC

Winsten

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mei 2026, 23:07 UTC

Winsten

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mei 2026, 23:06 UTC

Winsten

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mei 2026, 23:06 UTC

Winsten

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mei 2026, 23:05 UTC

Winsten

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mei 2026, 23:04 UTC

Winsten

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mei 2026, 22:50 UTC

Winsten

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mei 2026, 22:25 UTC

Marktinformatie

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mei 2026, 22:11 UTC

Winsten

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mei 2026, 22:11 UTC

Winsten

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mei 2026, 22:05 UTC

Marktinformatie

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mei 2026, 21:58 UTC

Winsten

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mei 2026, 21:47 UTC

Marktinformatie

Winsten

Costco Posts 13% Sales Growth in April -- Market Talk

6 mei 2026, 21:46 UTC

Winsten

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mei 2026, 21:40 UTC

Winsten

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mei 2026, 21:35 UTC

Marktinformatie

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mei 2026, 21:32 UTC

Populaire aandelen

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mei 2026, 21:29 UTC

Winsten

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Peer Vergelijking

Prijswijziging

Halozyme Therapeutics Inc Prognose

Koersdoel

By TipRanks

40% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 90.4 USD 40%

Hoogste 96 USD

Laagste 75 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Halozyme Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Halozyme Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

60.49 / 70.14Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

7 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.